Novartis Ag (NVS) 82.21 $NVS Global Chronic Obstructive

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novartis Ag (NVS) 82.21 $NVS

Global Chronic Obstructive Pulmonary Disease Drugs Market Growth of 4.85% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Merck, Almirall, Novartis - Research and Markets
BusinessWire - Wed Aug 03, 12:23PM CDT
Research and Markets has announced the addition of the "Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020" report to their offering.
MRK: 57.66 (+0.01), NVS: 82.21 (-0.19)

Global Pharmaceuticals Market Analytics Report 2016 Featuring Pfizer, Roche, Merk & Co., Sanofi, Gilead Sciences, Johnson & Johnson, Novartis, Abbvie, Amgen, GSK - Research and Markets
BusinessWire - Wed Aug 03, 8:13AM CDT
Research and Markets has announced the addition of the "Pharmaceuticals Global Market Analytics Report 2016" report to their offering.
JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVS: 82.21 (-0.19)

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
PR Newswire - Wed Aug 03, 6:00AM CDT
Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
NVS: 82.21 (-0.19)

Xencor Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 02, 3:01PM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the second quarter ended June 30, 2016 and provided a review of pipeline and corporate highlights.
XNCR: 21.16 (+1.88), NVS: 82.21 (-0.19)

What Awaits Radius Health (RDUS) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:02AM CDT
Radius Health (RDUS) is scheduled to report second-quarter 2016 results on Aug 4.
IPXL: 31.62 (+0.65), RDUS: 53.00 (+4.02), IRWD: 14.24 (+0.41), NVS: 82.21 (-0.19)

Alcon achieves US approval for CyPass(R) Micro-Stent, a micro invasive surgical device to treat glaucoma
Globe Newswire - Tue Aug 02, 12:15AM CDT
Novartis International AG / Alcon achieves US approval for CyPass(R) Micro-Stent, a micro invasive surgical device to treat glaucoma . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.21 (-0.19)

Neurologists Report Increasing Payer Pressure For Disease-Modifying Therapies, Resulting In Suboptimal Treatment For Some Patients With Multiple Sclerosis
PR Newswire - Mon Aug 01, 10:40AM CDT
In the Q2 update of RealTime Dynamix(TM): Multiple Sclerosis, roughly one-quarter of the respondents reported increased payer restrictions for Teva's Copaxone while restrictions have eased somewhat for Sandoz's Glatopa, Novartis' Extavia and Biogen's Tecfidera. While half of the neurologists agreed that payers are becoming more aggressive with MS patient management, only one-quarter stated that payer policies are strongly influencing their use of specific DMT brands.
NVS: 82.21 (-0.19)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.00 (-0.34), ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), MRK: 57.66 (+0.01), PFE: 35.49 (+0.20), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.21 (-0.19)

CutisPharma Appoints Steven Dinh As Chief Scientific Officer
PR Newswire - Mon Aug 01, 5:00AM CDT
CutisPharma today announced the appointment of Steven Dinh, Sc.D., as Executive Vice President and Chief Scientific Officer. In this key role, Dinh will oversee the Company's efforts to develop its pipeline of drugs for New Drug Application (NDA) submission to the U.S. Food and Drug Administration.
NVS: 82.21 (-0.19)

What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVLS: 4.83 (+0.02), CYTR: 0.62 (unch), CEMP: 22.41 (+0.21), ACUR: 1.88 (+0.04), NVS: 82.21 (-0.19)

After Yesterday's Decline of 1.24%, Novartis Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 28, 1:21PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.57 to a high of $82.58. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $82.27 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 82.21 (-0.19)

Look for Shares of Novartis to Potentially Rebound after Yesterday's 1.24% Sell Off
Comtex SmarTrend(R) - Thu Jul 28, 1:19PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.57 to a high of $82.58. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $82.27 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 82.21 (-0.19)

Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 13.01 (+0.17), ANIP: 65.00 (+2.90), GSK: 44.82 (-0.21), NVS: 82.21 (-0.19)

Novartis (NVS) Beats Earnings & Sales in Q2
Ekta Bagri - Zacks Investment Research - Tue Jul 19, 1:07AM CDT
Novartis beat on earnings in the second quarter of 2016.
NVS: 82.21 (-0.19)

Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Globe Newswire - Tue Jul 19, 12:01AM CDT
Novartis International AG / Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 82.21 (-0.19)

Why Earnings Season Could Be Great for Novartis AG (NVS)
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 9:12AM CDT
Novartis AG (NVS) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Rank perspective.
NVS: 82.21 (-0.19)

Abbott Labs (ABT) Q2 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
Abbott Laboratories (ABT) is scheduled to report second-quarter 2016 results before the opening bell on Jul 20.
ABT: 44.95 (-0.12), JNJ: 124.45 (+0.55), GILD: 80.37 (+0.28), NVS: 82.21 (-0.19)

3 Drug Stocks to Report Earnings on Jul 19: JNJ, NVS, NEOG
Arpita Dutt - Zacks Investment Research - Mon Jul 18, 7:02AM CDT
Three drug stocks including industry bellwether Johnson & Johnson (JNJ) will report results on Jul 19.
JNJ: 124.45 (+0.55), AMGN: 173.43 (-0.72), NEOG: 55.27 (-0.14), NVS: 82.21 (-0.19)

Global Psoriasis Market Outlook to 2020 - Key Players are Johnson and Johnson, Abbvie, Amgen & Novartis - Research and Markets
BusinessWire - Mon Jul 18, 6:18AM CDT
Research and Markets has announced the addition of the "Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020" report to their offering.
NVS: 82.21 (-0.19)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading